Sort By

SRC Family Negative Regulatory (pY) Site Polyclonal Antibody (Invitrogen™)

SRC Family Negative Regulatory (pY) Site Polyclonal Antibody for Western Blot

SRC N1 Recombinant Human Protein

SRC is a cytoplasmic tyrosine kinase and proto-oncogene involved in the regulation of embryonic development and cell growth. SRCN1 is a neuronal splice variant of SRC.

FL - SRC 1-1 Peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

FL - SRC 1-2 Peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

Phospho-SRC (Tyr418) Polyclonal Antibody (Invitrogen™)

Phospho-SRC (Tyr418) Polyclonal Antibody for Western Blot, IHC (P)

Fl - SRC 2-3 peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

FL - SRC 1-3 Peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

Phospho-SRC (Tyr418) Monoclonal Antibody (SC1T2M3), eFluor 660, eBioscience™ (Invitrogen™)

Phospho-SRC (Tyr418) Monoclonal Antibody for Flow

SRC Monoclonal Antibody (184Q20) (Invitrogen™)

SRC Monoclonal Antibody for Western Blot, IHC (P)

FL - SRC 3-3 Peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

FL - SRC 3-1 Peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

FL - SRC 1-4 Peptide

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.

Phospho-SRC (Tyr418) Monoclonal Antibody (SC1T2M3), PE, eBioscience™ (Invitrogen™)

Phospho-SRC (Tyr418) Monoclonal Antibody for Flow

SRC Polyclonal Antibody (Invitrogen™)

SRC Polyclonal Antibody for Western Blot, IHC (P)

Fl - SRC 2-1 peptide, 100µM

LanthaScreen® fluorescent nuclear receptor coregulator peptides contain known interaction motifs and are labeled with fluorescein. These peptides are matched and validated to complement the LanthaScreen® TR-FRET Nuclear Receptor Coregulator Assays. Assays developed using these reagents enable primary or secondary screening of nuclear receptor agonists and/or antagonists.

How they work
Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen® panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide. In the LanthaScreen® TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide (Figure 1). The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio (Figure 2).

Contents and Storage:

LanthaScreen® fluorescent nuclear receptor coregulator peptides are supplied as 100 µM solutions in peptide-appropriate buffers. Store peptides at -20°C.